Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov-Dec;22(6):1410-1415.

EGFR mutations and tumor metastases in patients with nonsmall cell lung cancer in the South of Russia

Oleg I Kit  1 , Dmitry I Vodolazhsky, Natalia N Timoshkina, Lubov' Yu Vladimirova, Igor N Turkin, Ksenia A Kutsyn, Yaroslav S Enin, Svetlana B Panina, Vladimir Jurisic
Affiliations
  • PMID: 29332331
Free article

EGFR mutations and tumor metastases in patients with nonsmall cell lung cancer in the South of Russia

Oleg I Kit et al. J BUON. 2017 Nov-Dec.
Free article

Abstract

Purpose: To assess the frequencies of somatic EGFR mutations in the tumor tissues of patients with non-small cell lung cancer (NSCLC) residing in the South of Russia (SR), and to define the relationship between genetic subtypes of NSCLC and the emergence of different types of metastases.

Methods: DNA was extracted from formalin-fixed parrafin embedded (FFPE) samples of 721 patients. A total of 29 somatic EGFR mutations were detected using commercial Therascreen EGFR RGQ PCR Kit.

Results: EGFR mutations were significantly more frequent in females and non-smokers even when considering the combination of both factors. The frequency of activating EGFR mutations across three age groups (<51, 51-61, >61 years) of women with NSCLC was significantly different (x2=10.94, p=0.004) and became higher with increasing age. Both activating and resistance mutations of EGFR were not associated with the frequency of regional or distant metastases. The frequencies of both regional and distant metastases were associated with higher disease stage (odds ratio/OR)=16.71; 95% confidence interval (CI): 9.5-29.38; p<0.0001, and OR=2.94; 95% CI: 2.22-3.88; p<0.0001, respectively) and adenocarcinona histology (OR=6.52; 95% CI: 2.03-20.92; p=0.002, and OR=1.99; 95% CI: 0.91-4.34; p=0.083, respectively) even when adjusted for age, gender, and smoking status. The risk for regional metastases development was associated with poor tumor differentiation (OR=2.91; 95% CI: 1.21-7.02; p=0.017).

Conclusion: EGFR mutations were not associated with the frequency of regional or distant metastases in SR patients with NSCLC.

PubMed Disclaimer